A common medication used to treat HIV and hepatitis B may offer unexpected protection against Alzheimer's disease.

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

NEW YORK (Reuters) -Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the ...

Existing drugs taken by thousands of people for another health condition may protect against dementia, a study suggests. US ...

On April 22, the CDC allegedly informed Emory University in Atlanta that its large HIV self-testing program was being ...

Communities in the Kenya’s and Uganda’s shores of Lake Victoria, Copperbelt Province in Zambia, Eastern Cape Province in ...

Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims it used speaker ...

Two new ways of giving the HIV medicine Dolutegravir to newborn babies have been found to be safe and effective, according to ...

Moving misbranded and adulterated HIV drugs from the black market to retail pharmacies and HIV patients was a $60 million ...

“For students aged 13 to 19, 4% of them were confirmed to have HIV, mostly from sexual activity. “The largest groups are ...